Enalapril, compared with placebo, decreases patient mortality in NYHA classes II and III heart failure (p = 0.0036).
ACE: angiotensin-converting enzyme; HF: heart failure; NYHA: New York Heart Association.
Data from: The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325:293.
